Public Comment of Dr. Diana Zuckerman, President National Center for Health Research At the FDA Advisory Committee meeting on Rexulti for Alzheimer’s patients April 14, 2023

April 14, 2023: Rexulti is already FDA approved as an atypical antipsychotic and FDA held an Advisory Committee meeting in April 2023 to consider approving it for agitation in dementia patients, many of whom are in nursing homes. We expressed concerns about Rexulti’s well-known risks of death for dementia patients. Why isn’t FDA more concerned about safety?

Read More »

NCHR addresses proposed changes to acne medicine iPLEDGE program

March 29, 2023: NCHR testimony at an FDA advisory committee recommends changes to the iPLEDGE REMS (risk reduction) program for patients taking the acne medication isotretinoin, which causes birth defects. We recommend eliminating unnecessary barriers for women who are unable to become pregnant and strengthening contraceptive requirements for adolescents.

Read More »